### ACNE PRODUCTS (topical)
- Erythromycin 2% solution (60ml)
- Clindamycin 1% swab (#60)
- Benzoyl Peroxide 2.5%, 5%, 10% gel (60g)
- Tretinoin 0.025%, 0.05%, 0.1% (60g)

### ACNE PRODUCTS (oral)
- Doxycycline 50, 100 mg caps
- Minocycline 50, 100 mg caps

*Isotretinoin* 10, 20, 30, 40 mg caps

### ANTI-INFECTIVES (topical)
- Bacitracin 500 U (30g)
- Bacitracin/polymyxin 500/10000 U/gm (30g)
- Mupirocin 2% oint (22g)
- Silver sulfadiazine 1% cream (50, 85, 400g)
- Sulfacetamide 10% lotion (120ml)

### ANTI-INFECTIVES (oral)
- Minocycline 0.025%, 0.05%, 0.1% (60g)
- Doxycycline 2.5%, 5%, 10% gel (60g)
- Hydroxyzine HCL 1% cream (30g)
- Terbinafine 0.5% soln (3.5ml)

### ANTI-ITCH (topical)
- Colloidal Oatmeal powder packet (#8)
- Camphor 0.5%/Menthol 0.5% (Sarna) Lotion (7.5oz)
- Clobetasol 10 mg tabs
- Cenixone 25, 50 mg caps
- Dicloxacillin 250, 500, 750 mg tabs
- Levofloxacin 250, 500, 750 mg tabs

### ANTI-ITCH (oral)
- Cetirizine 10 mg tabs
- Diphenhydramine 25m, 50 mg caps
- Doxepin 10, 25 mg caps
- Hydroxyzine HCL 10, 20, 50 mg tabs
- Loratadine 10 mg tabs

### ANTI-FUNGAL (oral)
- Fluconazole 150, 200 mg tabs
- Terbinafine 250 mg tabs

### ANTI-FUNGAL (topical)
- Clotrimazole 1% cream (15g)
- Ketoconazole 2% cream (30g), shampoo (120ml)
- Metronidazole 0.75% cream (45g)
- Miconazole 2% cream (30g), tincture (30ml)
- Nystatin Powder (30g)
- Podofilox 0.5% soln (3.5ml)
- Terbinafine 1% cream (30g)

### ANTI-PSORIATICS (topical)
- Coal tar Emulsion 7.5% (180ml)
- Shampoo 0.5% (255ml), 1% (180ml)
- Calcipotriene 0.005% cream (60g)

### ANTI-PSORIATICS (oral)
- Acitretin 10, 25 mg caps
- *Azathioprine* 50 mg tabs
- *Methotrexate* 2.5 mg tabs

### CORTICOSTEROIDS (topical)
- Clobetasol soln (25ml)
- Desonide 0.05% cream (60g)
- Fluocinolone acetonide 0.01% soln (60ml)
- Fluocinolone 0.05% cream, oint (60g)
- Flurandrenolide (Cordran) 4mg/sqcm tape (80in)
- Halobetasol 0.05% cream (50g), oint (15,50g)
- Hydrocortisone 1%, 2.5% cream (30g)
- Triamcinolone 0.025% cream (15g), oint (80g)
- 0.1% cream (15g), oint (15g, 45.45g)

### CORTICOSTEROIDS (oral)
- Prednisone 5, 10, 20 mg tabs
- Dexamethasone 0.5, 0.75, 2, 4 mg tabs

### MISCELLANEOUS
- Calamine Lotion (180ml)
- Folic acid 1mg tabs
- Hydrophilic (Eucerin) Cream (120, 454g)
- Hydroquinone 4% cream (30g)
- Lanolin hydrous oint (30g)
- Fluoroauracil 2% solution (10ml)
- Sunscreen (Zinc Oxide) SPF 30-50 lotion (120ml)
- Zinc Oxide 20% oint (60g)
- Hydroxychloroquine 200 mg tabs

### EMOLLIENTS/KERATOLYTICS
- Ammonium lactate 12% lotion (225ml)
- Petrolatum oint (30, 454g)
- Urea 10% lotion (240ml)
- Salicylic acid 3% shampoo (120ml)
- Salicylic acid/Sulfur 40% plaster (#1)
- Salicylic acid/Sulfur 2%/2% shampoo (120ml)

### SCABICIDES/PEDICULOCIDES
- Permethrin 1% liquid (60ml), 5% cream (60g)
- Ivermectin* 3mg tabs

1. Restricted to inadequate response or documented ADR to clotrimazole
2. Restricted to permethrin failure or crusted scabies
3. Restricted to DJD/zoster/peripheral neuropathy

---

**Prescribing Guideline**
- All Choice Program prescriptions require a Choice Network Provider Authorization form.
- Other agents may be available, but are restricted to VA criteria for use.
- For restricted medications in italic and those restricted to VA criteria for use, please annotate rationale for use.

Please visit the following link for more information on medication criteria:
http://www.pbm.va.gov/clinicalguidance/criteriawse.asp
<table>
<thead>
<tr>
<th>Drug Monitoring</th>
<th>Laboratories</th>
<th>Frequency of Monitoring</th>
<th>Required/Recommended</th>
<th>Black Box Warning/ Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Isotretinoin (Accutane)</strong></td>
<td>Serum HCG</td>
<td>Baseline prior to dispensing</td>
<td>Required</td>
<td>Teratogenic. Contraindication in pregnancy. Must be prescribed under I pledge Monitoring Program. Increased risk of depression/suicidality.</td>
</tr>
<tr>
<td></td>
<td>Monthly</td>
<td>Required</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>At completion of therapy</td>
<td>Required</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>1 month post discontinuation</td>
<td>Required</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>LFTs &amp; Lipid panel</td>
<td>Baseline (w/in 6 months)</td>
<td>Recommended</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Every 4 weeks until response established</td>
<td>Recommended</td>
<td></td>
</tr>
<tr>
<td><strong>Azathioprine 6-Mercaptopurine</strong></td>
<td>CBC</td>
<td>Baseline prior to dispensing</td>
<td>Required</td>
<td>Metabolic acidosis may occur at any time during treatment but especially in treatment and in patients with preexisting conditions such as renal disease, severe respiratory disorders, status epilepticus, diarrhea, surgery, or in patients receiving concomitant drug therapies which have additive bicarbonate lowering effects and in ketogenic diets.</td>
</tr>
<tr>
<td></td>
<td>Weekly for the 1st month</td>
<td>Required</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Every other week for month 2 &amp; 3</td>
<td>Required</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Monthly thereafter</td>
<td>Required</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>TMPT (Thiopurine methyltransferase)</td>
<td>Baseline prior to dispensing</td>
<td>Recommended</td>
<td></td>
</tr>
<tr>
<td></td>
<td>LFTs</td>
<td>Baseline prior to dispensing</td>
<td>Recommended</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Bi-weekly for the 1st month</td>
<td>Recommended</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Monthly thereafter</td>
<td>Recommended</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Methotrexate</strong></td>
<td>CBC, SCr, LFTs, Alk Phos</td>
<td>Baseline (w/in 6 months)</td>
<td>Required</td>
<td>Bone marrow suppression, hepatotoxicity, lung toxicity, malignant lymphomas, tumor lysis syndrome, skin reactions and fetal opportunistic infections have been reported. Preservative containing formulations or diluents not used for intrathecal or high dose use. Teratogenic. Not recommended for women of child bearing potential unless benefit-risk ratio is acceptable. Elimination is reduced in impaired renal fxn, ascites, or pleural effusions &amp; requires dose reduction.</td>
</tr>
<tr>
<td></td>
<td>CBC</td>
<td>Every 6 months</td>
<td>Required</td>
<td></td>
</tr>
<tr>
<td></td>
<td>LFTs, SCr</td>
<td>Every 8 weeks</td>
<td>Recommended</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chest Xray</td>
<td>Baseline within prior year</td>
<td>Required</td>
<td></td>
</tr>
<tr>
<td></td>
<td>HCG</td>
<td>Baseline prior to dispensing</td>
<td>Required</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Hepatitis B and C serology in high risk patients</td>
<td>Baseline (w/in 6 months)</td>
<td>Recommended</td>
<td></td>
</tr>
</tbody>
</table>